Interview: Frank Douglas – CEO, TheVax Genetics, Taiwan

Frank Douglas, CEO of the TheVax, discusses what he finds so inspiring about innovation in resource-constrained environments, and this Taiwanese biotech’s revolutionary SIT specific immunotherapy platform. The company was founded in 2012 with the mission to focus on the use of immunotherapy to address virus-induced tumors and infections in patients. Could you explain how the company was founded and how you became CEO of the TheVax Genetics Vaccine USA?
"The Specific Immunological Therapeutic (SIT) approach represents a technology platform with potential for application in several diseases."
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report